Atorvastatin-Ezetimibe
ApprovedSmall molecule
Atorvastatin-Ezetimibe is one of 50 small molecule programs targeting Atherosclerosis. It is currently in Approved.
2
Indications
3
Total Trials
1
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Atorvastatin-Ezetimibe
SSeoul National University Bundang Hospital
Approved
Biaxin
AbbViePreclinical
Angiomax
BBaxter Healthcare Corporation
Preclinical
Proventil
Mylan Pharmaceuticals IncPreclinical
Low-Molecular-Weight Heparin
Daiichi SankyoPreclinical
SARS-COV-2 VACCINE
ModernaPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Blood Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Blood Taken
HHospices Civils de Lyon
Preclinical
Hydroxychloroquine Pill
UUniversity of Calgary
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atherosclerosis1 trial
COVID-191 trial
Evaluation of the Effect of Long-term Lipid-lowering Therapy in STEMI Patients With Coronavirus Infection COVID-19
Unknown status·—·N/A·NCT04900155·45 enrolled
Treatment1 trial
A Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis
Unknown status·—·Phase 4·NCT00433823
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Atorvastatin-Ezetimibe. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details